Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 90Thoracic 68Breast 27Gynecologic 26Head & Neck 18Lymphoid 10Sarcoma 8Other hematologic neoplasm 8Genitourinary 7CNS 7Other solid neoplasm 6Tumor-Agnostic 5Endocrine 3NET 2Dermatologic 2

Conditions

Neuroendocrine Tumors 1Carcinoma, Neuroendocrine 1Advanced Pancreatic Neuroendocrine Tumor 1

Interventions

lutetium Lu 177 dotatate 15Magnetic Resonance Spectroscopy 9Everolimus 8gallium Ga 68 dotatate 6lanreotide 4cabozantinib 4Temozolomide 4Specimen Handling 4Nivolumab 4Lutetium-177 4Lutetium 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4surufatinib 3olaparib 3copper dotatate CU-64 3Somatostatin 3Injections 3Ga(III)-DOTATOC 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Capecitabine 3pembrolizumab 2fludarabine phosphate 2fludarabine 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Sunitinib 2Radiosurgery 2Octreotide 2Drug Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Drug Therapy × NET × Clear all
NCT04464122 2025-04-03

REBORN

University of Roma La Sapienza

Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06246630 2024-05-16

In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor

Ruijin Hospital

Phase NA Recruiting
20 enrolled
EndocrineGastrointestinalNET

Advanced Pancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡